EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy

John W Ostrominski, Ruby Guo, Perry M Elliott, Carolyn Y Ho

JACC: Heart Failure · 2023-07 · 11 (7) · 735-748

DOI: 10.1016/j.jchf.2023.04.018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JACC: Heart Failure, 2023-07. Verfasst von John W Ostrominski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Heart Failure, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is frequently caused by pathogenic variants in genes encoding sarcomere proteins and is characterized by left ventricular (LV) hypertrophy, hypercontractility, and-in many cases-left ventricular outflow tract (LVOT) obstruction. Despite standard management, obstructive HCM (oHCM) can still cause substantial morbidity, highlighting the critical need for more effective disease-specific therapeutic approaches. Over the past decade, improved understanding of the molecular pathobiology of HCM has culminated in development of cardiac myosin inhibitors (CMIs), a novel drug class that in recent randomized clinical trials has been shown to decrease LVOT obstruction, improve exercise capacity, and ameliorate symptom burden in patients with oHCM. Although promising, areas of uncertainty remain, including the long-term safety and efficacy of CMIs and whether they have the potential to modify progression of disease. Herein, we review key milestones in the clinical development of CMIs, contextualize CMIs with established oHCM therapies, and discuss future challenges and opportunities for the use of CMIs across the HCM spectrum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCardiomyopathy, HypertrophicHumansCardiac MyosinsHypertrophy, Left Ventricular

Stichwörter der Autor:innen

clinical trialsgeneticheart failurehypertrophic cardiomyopathymyosin modulatorsobstructionsarcomere

Substanzen

Cardiac Myosins

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Centre for Heart Muscle Disease, Institute of Cardiological Sciences, University College London and St Bartholomew's Hospital, London, United Kingdom.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: cho@bwh.harvard.edu.

Zitieren

APA

Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023). Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure, 11(7), 735-748. https://doi.org/10.1016/j.jchf.2023.04.018

Vancouver

Ostrominski JW, Guo R, Elliott PM, Ho CY. Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure. 2023;11(7):735-748. doi:10.1016/j.jchf.2023.04.018

BibTeX
@article{Ostrominski2023,
  author = {Ostrominski, John W and Guo, Ruby and Elliott, Perry M and Ho, Carolyn Y},
  title = {Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy},
  journal = {JACC: Heart Failure},
  year = {2023},
  volume = {11},
  number = {7},
  pages = {735--748},
  doi = {10.1016/j.jchf.2023.04.018}
}
Kostenlos starten →